This new report from VPGMarketResearch.com provides the 2024 sales, market shares, and strategic profiles of major distributors of Medical Research and Clinical Lab Products.

The companies analyzed in the report include:

Agility Alcon/Novartis Alma Lasers/Sisram Bausch & Lomb Biolase Carl Zeiss Condela Cutera Cynosure Fortec Medical Fotona Healthtronics IPG Photonics Iridex J&J/Abbott Lensar Lumenis Lutronic MedLaserUSA Quantel/Ellex/Lumibird Syneron Candela Topcon Trimedyne Ziemer

Tables

2024 Ophthalmology Surgical Laser Market Sales and Shares of Major Suppliers

2024 Dermatology Surgical Laser Market Estimated Sales and Shares of Major Suppliers

2024 Surgical Laser Rental Market Estimated Sales and Shares of Major Suppliers

The Dermatology Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such As the Impact of Skin Disease on Quality Of Life and the Resulting Need to Tackle This Are Driving the Market Growth
WHO (World Health Organization) defined it as disability in skin conditions that impact the well-being, mental health, ability to function, and social participation and restrict engagement with others. Quality of life (QoL) tools help in these and some of the tools include the Dermatology Life Quality Index (DLQI) and the Skindex. The QoL can be impaired for a variety of reasons mainly due to symptoms of the disease. Atopic eczema is one disease where the psychological burden is particularly pronounced. Psychosomatic involvement is the main characteristic of atopic...

The Dermatology CROs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region.

Reduced market time, reduced infrastructure costs, and improved operational efficiency to drive the market growth
Reduced market time, infrastructure costs, and operational benefits are some of the major forces driving the dermatology CRO market. The expansion or localization of contract services by countries is expected to result in significant investments in facilities, equipment, and skilled labour. Furthermore, some countries with low resources are unable to manufacture vaccines due to a lack of equipment and experienced personnel. This causes the countries to create contracts with contract producers in order to meet the demands of the market.

Considering the COVID-19 pandemic, the co...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysi...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis - Pipeline Review, H1 2020, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the...

Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
- Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of curre...

Summary

Atopic dermatitis (AD) or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Although the condition affects people of all ages, it is primarily common among infants and children. Modifiable risk factors include inhalant allergens, food allergens, and newborns not being exclusively breastfed, while non-modifiable risk factors include young age and genetics or heritability.

This epidemiology forecast for AD is supported by historical data obtained from peer-reviewed articles and population-based studies. These sources used questionnaires and various diagnostic measures to assess AD symptoms across the 7MM. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of AD across these markets.

In the 7MM, the one-year total prevalent cases of AD are expected to increase from 81,608,107 cases in 2017 to 83,639,767 cases in 2027, at an Annual Growth Rate (AGR) of 0.25%. In the 7MM, the one-year diagnosed prevalent cases of AD are expected to increase from 36,109,87...

Summary

Dermatology is a highly diverse therapy area, in terms of severity and clinical presentation, which deals with diseases of the skin, hair and nails. Whilst an orphan disease is a disease that is neglected in terms of research and funding and in the US, a disease is considered to be rare if it affects fewer than 200,000 people.

Many orphan and rare dermatology disorders are associated with significant quality of life impairments, particularly if the disease is insufficiently controlled. In particular, disease visibility can have a profoundly negative impact on patient confidence. However, the current therapeutics market is a highly genericized therapy area and there exists a significant unmet need for more efficacious and safer treatment options that treat the underlying causes of disease as opposed to managing the symptoms.

This report covers all orphan and rare dermatology disorders, but there is a particular focus on six key diseases, systemic sclerosis (scleroderma), alopecia, epidermolysis bullosa, pemphigus vulgaris, vitiligo and cutaneous ...

Summary

This report provides an overview of the pipeline landscape for dermatological burns, scars and ulcers. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for pressure ulcers, venous leg ulcers, burns and scars, and features dormant and discontinued products.

A pressure ulcer is an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition. There are six products in development for this indication.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of a finger w...

Summary

Orphan and rare dermatological diseases are considerably diverse in terms of pathophysiology, clinical presentation and disease severity. Many of these conditions are extremely debilitating and can even be life-threatening in some cases.

Disease visibility can also have a profoundly negative impact on patient confidence. Unmet need within the orphan and rare dermatology market is extremely high with some diseases having no effective treatments. The market is highly genericized and dominated to a large extent by products acting on hormones and their receptors.

Most of these are corticosteroids and are used for symptom management with no disease-modifying effects. There is a significant unmet need for more efficacious disease-modifying treatments and safer treatment options across orphan and rare dermatological diseases, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues associated with the long-term use of available treatments.

This report covers all orphan and rare dermatology disorder...

Summary

GlobalData's clinical trial report, “Atopic Dermatitis Global Clinical Trials Review, H2, 2016" provides an overview of Atopic Dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Atopic Dermatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain compe...

Summary

GlobalData's clinical trial report, “Dermatitis Global Clinical Trials Review, H2, 2016" provides an overview of Dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
...

Summary

Global Markets Direct’s, ‘Atopic Dermatitis - Pipeline Review, H2 2016’, provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, inve...

Summary

GlobalData's clinical trial report, “Seborrhea Global Clinical Trials Review, H1, 2016" provides an overview of Seborrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Seborrhea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
$2,500.00 ]]> Tue, 07 Jun 2016 09:32:09 +0000 https://www.leadingmarketresearch.com/acne-vulgaris-global-clinical-trials-review-h1-2016

Summary

GlobalData's clinical trial report, “Acne Vulgaris Global Clinical Trials Review, H1, 2016" provides an overview of Acne Vulgaris clinical trials scenario. This report provides top line data relating to the clinical trials on Acne Vulgaris. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advan...

Summary

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growt...